Orlando

For decades, CLL patients faced a Faustian bargain: take a pill every day for the rest of your life, or risk relapse.

Yesterday’s plenary session at ASH suggested we might finally escape this trade-off, though as with most things in oncology, the devil lives in the details.

Those details extended to updates on BTK degraders, where early data sparked the usual premature comparisons whilst a sobering resistance mechanism reminded us why we can’t declare victory yet.

To continue reading our latest highlights on oncology new product development including commentary and analysis BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers